We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
[<sup>18</sup>F]‐FDG PET radiomic model as prognostic biomarker in diffuse large B‐cell lymphoma.
- Authors
Travaini, Laura Lavinia; Botta, Francesca; Derenzini, Enrico; Lo Presti, Giuliana; Ferrari, Mahila Esmeralda; Airò Farulla, Lighea Simona; Radice, Tommaso; Mazzara, Saveria; Tarella, Corrado; Pileri, Stefano; Raimondi, Sara; Ceci, Francesco
- Abstract
To evaluate the association between radiomic features (RFs) extracted from 18F‐FDG PET/CT (18F‐FDG‐PET) with progression‐free survival (PFS) and overall survival (OS) in diffuse large‐B‐cell lymphoma (DLBCL) patients eligible to first‐line chemotherapy. DLBCL patients who underwent 18F‐FDG‐PET prior to first‐line chemotherapy were retrospectively analyzed. RFs were extracted from the lesion showing the highest uptake. A radiomic score to predict PFS and OS was obtained by multivariable Elastic Net Cox model. Radiomic univariate model, clinical and combined clinical‐radiomic multivariable models to predict PFS and OS were obtained. 112 patients were analyzed. Median follow‐up was 34.7 months (Inter‐Quartile Range (IQR) 11.3–66.3 months) for PFS and 41.1 (IQR 18.4–68.9) for OS. Radiomic score resulted associated with PFS and OS (p < 0.001), outperforming conventional PET parameters. C‐index (95% CI) for PFS prediction were 0.67 (0.58–0.76), 0.81 (0.75–0.88) and 0.84 (0.77–0.91) for clinical, radiomic and combined clinical‐radiomic model, respectively. C‐index for OS were 0.77 (0.66–0.89), 0.84 (0.76–0.91) and 0.90 (0.81–0.98). In the Kaplan‐Meier analysis (low‐IPI vs. high‐IPI), the radiomic score was significant predictor of PFS (p < 0.001). The radiomic score was an independent prognostic biomarker of survival in DLBCL patients. The extraction of RFs from baseline 18F‐FDG‐PET might be proposed in DLBCL to stratify high‐risk versus low‐risk patients of relapse after first‐line therapy, especially in low‐IPI patients.
- Subjects
DIFFUSE large B-cell lymphomas; PROGNOSTIC models; BIOMARKERS
- Publication
Hematological Oncology, 2023, Vol 41, Issue 4, p674
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3171